Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (71-80 of 250) with videos related to

Pageof 25
Sort By:
Clinical Therapeutics|March 9, 2019
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple SclerosisPatrick Vermersch, Vittorio Martinelli, Claudia Pfleger, et al.
Immunology Letters|October 16, 2010
Susceptibility to experimental autoimmune encephalomyelitis is associated with altered B-cell subsets distribution and decreased serum BAFF levelsCatalina Lee-Chang, Didier Lefranc, Julia Salleron, et al.
Nature Reviews. Neurology|September 9, 2024
Assessing disease progression and treatment response in progressive multiple sclerosisGiancarlo Comi, Gloria Dalla Costa, Bruno Stankoff, et al.
Neurourology and Urodynamics|December 11, 2023
Response to tibial and sacral nerve modulation in overactive bladder: Is there any correlation?Mathieu Fourel, Samy Hafez, Nassima Ramdane, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 6, 2008
Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assayCatherine Massart, Jacqueline Gibassier, Jérôme de Seze, et al.
Clinical Immunology (Orlando, Fla.)|February 12, 2011
Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosisCatalina Lee-Chang, Isabelle Top, Hélène Zéphir, et al.
Neurology and Therapy|June 5, 2026
A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple SclerosisClair-Antoine Veyrier, Patrick Vermersch, Olivier Casez, et al.
Multiple Sclerosis and Related Disorders|March 4, 2026
Psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 questionnaires in relapsing multiple sclerosis participants enrolled in a phase 2 trial of frexalimabPatrick Vermersch, Lita Araujo, Samuel Gourlain, et al.
Plos One|May 14, 2025
Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative diseaseOlivier Hermine, Laurent Gros, Truong-An Tran, et al.
BMC Neurology|June 14, 2012
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot studyPatrick Vermersch, Rabah Benrabah, Nicolas Schmidt, et al.
Pageof 25

Showing results (71-80 of 250) with videos related to

Sort By:
Pageof 25
Clinical Therapeutics|March 9, 2019
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple SclerosisPatrick Vermersch, Vittorio Martinelli, Claudia Pfleger, et al.
Immunology Letters|October 16, 2010
Susceptibility to experimental autoimmune encephalomyelitis is associated with altered B-cell subsets distribution and decreased serum BAFF levelsCatalina Lee-Chang, Didier Lefranc, Julia Salleron, et al.
Nature Reviews. Neurology|September 9, 2024
Assessing disease progression and treatment response in progressive multiple sclerosisGiancarlo Comi, Gloria Dalla Costa, Bruno Stankoff, et al.
Neurourology and Urodynamics|December 11, 2023
Response to tibial and sacral nerve modulation in overactive bladder: Is there any correlation?Mathieu Fourel, Samy Hafez, Nassima Ramdane, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 6, 2008
Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assayCatherine Massart, Jacqueline Gibassier, Jérôme de Seze, et al.
Clinical Immunology (Orlando, Fla.)|February 12, 2011
Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosisCatalina Lee-Chang, Isabelle Top, Hélène Zéphir, et al.
Neurology and Therapy|June 5, 2026
A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple SclerosisClair-Antoine Veyrier, Patrick Vermersch, Olivier Casez, et al.
Multiple Sclerosis and Related Disorders|March 4, 2026
Psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 questionnaires in relapsing multiple sclerosis participants enrolled in a phase 2 trial of frexalimabPatrick Vermersch, Lita Araujo, Samuel Gourlain, et al.
Plos One|May 14, 2025
Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative diseaseOlivier Hermine, Laurent Gros, Truong-An Tran, et al.
BMC Neurology|June 14, 2012
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot studyPatrick Vermersch, Rabah Benrabah, Nicolas Schmidt, et al.
Pageof 25